Tropism Guidelines

The European Consensus on clinical management of HIV-1 tropism testing has developed guideline for the use of tropism tests. These Guidelines have been published in the Lancet Infectious Diseases and can be download from the publisher website:

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(10)70319-4/fulltext

A word version of the document is accessible on this page. 

Background
Co-receptor tropism refers to the ability of HIV-1 to utilize the human chemokine receptors CCR5 (R5-virus), CXCR4 (X4-virus), or both (dual-tropic viruses or mixed populations of R5- and X4- viruses) for viral entry into CD4 cells. Following the FDA/EMEA approval of the first CCR5-coreceptor antagonist, which only inhibits R5-viruses, pre-assessment of viral tropism is required for clinical use.
Active exchange of procedures for tropism testing is sought in Europe in order to optimise and standardise available tropism determination techniques. Guidelines advise on the optimal clinical management of tropism testing and will be regularly be updated to reflect upcoming developments.

Writing committee
LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vézinet, B Clotet, A De Luca,  Dressler, F Garcia PhD, AM Geretti, T Klimkait, K Korn, B Masquelier, CF Perno, JM Schapiro, V Soriano, A Sönnerborg, A-M Vandamme, C Verhofstede, H Walter, M Zazzi, CAB Boucher, on behalf of the European Consensus Group on clinical management of tropism testing

European Consensus Group on clinical management of HIV-1 tropism testing
Austria Elisabeth Puchhammer-Stöckl (Department of Virology, Medical University Vienna, Vienna); Belgium Stephan Dressler (European AIDS Treatment Group, Brussels), Anne-Mieke Vandamme, Kristel Van Laethem (Laboratory for Clinical and Epidemiological Virology, AIDS Reference Laboratory, Rega Institute and University Hospitals, Leuven), Linos PR Vandekerckhove (Infectious Diseases Unit and AIDS Reference Laboratory, Ghent University Hospital, Ghent), Chirs Verhofstede (Infectious Diseases Unit, Ghent University Hospital, Ghent); Bulgaria Ivaylo A Ivanov, Danail A Beshkov (National HIV Confirmatory Laboratory, National Center of Infectious and Parasitic Diseases, Sofia); Croatia Snjezana Zidovec Lepej (University Hospital for Infectious Diseases, Zagreb); Cyprus Leondios G Kostrikis (Department of Biological Sciences, University of Cyprus, Nicosia); Czech Republic Marek Linka (National Institute of Public Health, Prague); Denmark Claus Nielsen (Statens Serum Institute, Copenhagen); Estonia Kai Zilmer (Tallinn Central Hospital, Centre for Infectious Diseases, Tallinn); Finland Kirsi Liitsola (National Institute of Health and Welfare, HIV Laboratory and Department, Helsinki); France Françoise Brun-Vézinet (Bichat Claude Bernard University Hospital, Paris), Bernard Masquelier (Laboratoire de Virologie, CHU de Bordeaux, Bordeaux); Germany Patrick Braun (PZB Aachen, Aachen), Martin Daeumer (Institute of Immunology and Genetics, Kaiserslautern), Rolf Kaiser (Institute of Virology, University of Cologne, Cologne), Klaus Korn, Hauke Walter (Institute of Clinical and Molecular Virology, University of Erlangen, Erlangen), Martin Obermeier (Medizinisches Labor Berg, Berlin); Greece Dimitrios Paraskevis (Department of Hygiene Epidemiology and Medical Statistics, Medical School, University of Athens); Hungary Janos Minarovits (National Public Health and Medical Officer Service, Budapest); Ireland Suzie Coughlan, Cillian de Gascun (National Virus Reference Laboratory, University College Dublin, Dublin); Israel Jonathan M Schapiro (National Hemophilia Center, Sheba Medical Center, Tel Aviv), Zehava Grossman (Sheba Medical Center, Tel-Hashomer, and School of Public Health, Tel-Aviv University, Tel-Aviv); Italy Claudia Balotta (Department of Clinical Sciences, Infectious Diseases and Immunopathology Section “L Sacco” Hospital, University of Milan, Milan), Andrea De Luca (UOC Malattie Infettive 2, Siena University Hospital, Siena and Istituto di Clinica delle Malattie Infettive, Catholic University, Rome), Carlo Federico Perno (Department of Experimental Medicine, University of Rome Tor Vergata, Rome), Stefano Rusconi (Sezione di Malattie Infettive e Immunopatologia, DISC “Luigi Sacco”, Universita' degli Studi di Milano), Valentina Svicher (Department of Experimental Medicine, University of Rome Tor Vergata, Rome), Maurizio Zazzi (Department of Molecular Biology, University of Siena, Siena); Latvia Tatjana Kolupajeva (Infectology Center of Latvia, Riga); Lithuania Algirdas Griskevicius (Centre for Communicable Diseases and AIDS Vilnius); Luxembourg Jean-Claude C Schmit (Centre Hospitalier de Luxembourg and Centre de Recherche Public de la Santé); Netherlands Charles A B Boucher (Department of Virology, Erasmus Medical Center, Rotterdam), Rob Schuurman, Annemarie J Wensing (University Medical Center Utrecht, Department of Virology, Medical Microbiology, Utrecht); Norway Birgitta Åsjö (Section for Microbiology and Immunology, Gade Institute, University of Bergen, Bergen); Poland Andrzej J W Horban (Warsaw Medical University and Hospital of Infectious Diseases, Warsaw); Portugal Ricardo J Camacho (Instituto de Higiene e Medicina Transfusional, Universidade Nova de Lisboa, Lisbon); Romania Luminita Ene (Dr Victor Babes Hospital for Infectious and Tropical Diseases, Bucharest), Dan Otelea (Molecular Diagnostics Laboratory, National Institute for Infectious Diseases, Bucharest); Serbia Maja Stanojevic (University of Belgrade School of Medicine Institute of Microbiology and Immunology, Belgrade); Slovakia Danica Stanékova (Slovak Medical University, Bratislava); Slovenia Mario Poljak (Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana); Spain Bonaventura Clotet (Retrovirology Laboratory IRSICAIXA Foundation, Badalona), Federico Garcia (Hospital Universitario San Cecilio, Granada), Roger Paredes (Retrovirology Laboratory IRSICAIXA Foundation, Badalona), Eva Poveda (Infectious Diseases Department, Hospital Carlos III, Madrid), Vincent Soriano (Department of Infectious Diseases, Hospital Carlos III, Madrid); Sweden Jan Albert (Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet and Department of Virology, Swedish Institute for Infectious Disease Control), Anders Sönnerborg (Divisions of Infectious Diseases and Clinical Virology, Karolinska Institutet, Karolinska University Hospital, Stockholm); Switzerland Thomas Klimkait (University of Basel, Department Biomedicine; Institute of Medical Microbiology, Basel), Sabine Yerly (Laboratory of Virology, Geneva's University Hospitals and University of Geneva Medical School, Geneva); UK Pat Cane (Virus Reference Department, Centre for Infections, Health Protection Agency, London), Anna Maria Geretti (Royal Free Hampstead NHS Trust and UCL Medical School, London), Deenan Pillay (Health Protection Agency and UCL Medical School, London).

For writing committee members there is a restricted area. Please use the login at the right to go to this area.